key: cord-0861751-7lbpmn48
authors: Qu, Rong; Ling, Yun; Zhang, Yi‐hui‐zhi; Wei, Li‐ya; Chen, Xiao; Li, Xu‐mian; Liu, Xuan‐yong; Liu, Han‐mian; Guo, Zhi; Ren, Hua; Wang, Qiang
title: Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19
date: 2020-03-26
journal: J Med Virol
DOI: 10.1002/jmv.25767
sha: be98e0dc16a230517ce9eb6bc6ab64ac4fc824b7
doc_id: 861751
cord_uid: 7lbpmn48

Since December 2019, novel coronavirus infected pneumonia emerged in Wuhan city and rapidly spread throughout China. In severe novel coronavirus pneumonia cases, the number of platelets, their dynamic changes during the treatment, platelet‐to‐lymphocyte ratio (PLR) were a concern. We sought to describe the platelet feature of these cases. Single‐center case series of the 30 hospitalized patients with confirmed coronavirus disease (COVID)‐19 in Huizhou municipal central hospital from January 2020 to February 2020 were retrospectively analyzed. Demographic, clinical, blood routine results, other laboratory results, and treatment data were collected and analyzed. Outcomes of severe patients and nonsevere patients were compared. Univariate analysis showed that: age, platelet peaks, and PLR at peak platelet were the influencing factors in severe patients, multivariate analysis showed that the PLR value at peak platelet during treatment was an independent influencing factor in severe patients. The average hospitalization day of patients with platelet peaks during treatment was longer than those without platelet peaks (P < .05). The average age of patients with platelet peaks during treatment was older than those without platelet peaks (P < .05). The patients with significantly elevated platelets during treatment had longer average hospitalization days. And the higher PLR of patients during treatment had longer average hospitalization days. Single‐center case series of the 30 hospitalized patients with confirmed COVID‐19 in Huizhou Municipal Central Hospital, presumed that the number of platelets and their dynamic changes during the treatment may have a suggestion on the severity and prognosis of the disease. The patient with markedly elevated platelets and longer average hospitalization days may be related to the cytokine storm. The PLR of patients means the degree of cytokine storm, which might provide a new indicator in the monitoring in patients with COVID‐19.

At present, there is no effective therapy for COVID-19. Therefore, the group of diseases and the assessment of prognosis become more and more important. 3 The severity of diseases was according to the COVID-19 diagnosis and treatment scheme issued by the National Health Committee. Patients were divided into four groups, including light groups, medium groups, severe groups, and critically ill groups.

However, platelet-to-lymphocyte ratio (PLR) of COVID-19 between severe and nonsevere cases were not fully reported, which may have prognostic values and be important therapeutic targets. In this study, the number of platelets, their dynamic changes during the treatment, PLR of 30 laboratory-confirmed cases admitted to Huizhou Municipal Central Hospital was showed, the difference between severe and nonsevere cases was investigated. Multivariate analysis of independent risk factors and relationship between PLR and prognosis.

Data are presented as mean and standard deviation unless stated otherwise. The nonparametric two-tailed Student t test was used to analyze variables. Differences in values between tested groups were regarded as significant at a value of P ≤ .05. Correlation analysis used simple linear correlation, multifactor logistic regression analysis.

Data were analyzed using SPSS 25. The optimal cut-off value, sensitivity (sensitivity), and specificity (specificity) of PLR were determined by analysis of receiver operating characteristic (ROC) curve. The statistical graphs were drawn using GraphPad Prism 6 software.

There were a total of 30 patients admitted with a median age of 

The correlation between two groups in terms of age, length of hospitalization, the absolute value of lymphocytes, platelets, and so on are shown in Table 1 and Figures 1 and 2. Table 1 shows the difference between nonsevere group and severe group in the average age (49.44 vs 60 years) and the average length of hospitalization (15.33 vs 27 days), the statistics of two groups was statistical significance (P < .05). We also analyze some other indicators between the two groups, such as platelet value, absolute lymphocyte values, PLR, ALT, and AST, LDH at admission. But there are no significance between them. Unexpectedly, comparing the peak of platelet, it was found that the average platelet peak during the treatment of severe patients was 392 × 10 9 /L, which was significantly higher than the nonsevere patients at 301 × 10 9 /L. The PLR was 626, which was significantly higher than the PLR of nonsevere patients, which was 262. The date of the two groups was statistically significant (P < .05). In terms of hormone use, a total of 18 nonsevere patients used hormones during treatment, accounting for 66.7% of nonsevere patients, and 3 of the severe patients had used hormones, accounting for 100%, but these two groups of data have no statistical significance. Multivariate logistic regression analysis of age, platelet peak, and PLR at platelet peak during treatment showed that PLR at platelet peak during treatment was an independent influencing factor for critically ill patients.

The results are shown in Table 2. 3.3 | Correlation between platelet trend and course of disease during treatment Figure 3 shows the trend of platelet in three severe patients. We found the same trend in three nonsevere patients. And their platelet value was above 300 × 10 9 /L. The platelet peak of group A was above 300 × 10 9 /L during the treatment. The platelet peak of group B was under 300 × 10 9 /L during the treatment. As shown in Table 3 , patients in group A was older than patients in group B. Patients in group A had longer average hospitalization day. The difference between the two groups is statistically significant (P < .05).

Comparing the correlation between the difference (ΔPLR) the PLR at the time of admission and the maximum of PLR during treatment, and the length of hospitalization day. The data are shown in COVID-19. 25, 26 However, there are many factors that affect platelet changes in the clinic. All patients in this study did not use invasive procedures such as tracheal intubation and deep vein catheterization. Therefore, the impact of invasive procedures on platelet changes was not considered in this article. 27 It can be seen from the foregoing that the use of hormones during the treatment of patients is not significantly different between severe and nonsevere patients, so their effects on platelets can also be ruled out.

As a new type of inflammation index, PLR mainly reflects the level of systemic inflammation. Previous studies have confirmed that PLR is closely related to tumors, diabetes, coronary heart disease, and connective tissue diseases, and the increase of PLR is related to tumor size, lymph node infiltration, distant metastasis and prognosis, and can be used as a potential inflammatory indicator for the clinical diagnosis of community-acquired pneumonia. 28 As an indicator of inflammation, Platelet-released platelet factor-4 can prevent agglutinin-A from inhibiting lymphocyte generation, and activated platelets enhance lymphocyte adhesion to the endothelium, thereby promoting lymphocyte homing in endothelial veins and migration to inflammatory sites. PLR refers to the ratio of the platelet-to-lymphocyte count. The advantage of PLR selection is that it reflects both aggregation and inflammatory pathways, and maybe more valuable in predicting various inflammations than platelet or lymphocyte counts alone.

The pathogenesis of COVID-19 is also related to the virus-induced inflammatory response in vivo. [30] [31] [32] According to the current clinical and relevant data, patients with lower lymphocyte levels at the first diagnosis are more seriously ill, and the progressive decline in lymphocyte proportion indicates a poor prognosis. According to prior analysis, we propose the PLR as an indicator which reflects the severity of inflammation in the process of treatment, by comparing the changes of PLR during treatment, we found that the higher the ΔPLR, the longer the hospital stay they were, of which showed a linear correlation.

Therefore, we speculated that the changes in the platelet/lymphocyte ratio in peripheral blood during treatment could reflect the disease progression and prognosis of COVID-19 patients. The larger the ΔPLR, the more severe the cytokine storm, and the longer the hospital stay, the worse the prognosis. When ΔPLR increases in severe patients, we increase thymosin to regulate immune to elevate lymphocyte therapy to improve this situation, to prevent the development of severe patients or promote the improvement of symptoms in severe patients. After active symptomatic treatment, all three severe patients were successfully treated and successfully discharged from the hospital! The results of this treatment also seem to confirm our conjecture. We also calculated the cut-off value of ΔPLR. When ΔPLR > 126.7, we must actively intervene to prevent further deterioration of the disease. However, due to the lack of clinical data, this conclusion may be biased, and a larger number of samples are needed for further confirmation. 

A novel coronavirus from patients with pneumonia in China

Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing

Potential antiviral therapeutics for 2019 novel coronavirus

Which lessons shall we learn from the 2019 novel coronavirus outbreak?

The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019

Genomic characterization and epidemiology of 2019 novel coronavirus: implications of virus origins and receptor binding

Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses

Potentbinding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific humanmonoclonal antibody

The effect of SARS coronavirus on blood system:its clinical findings and the pathophysiologichypothesis

Platelets in inflammation and infection

Relationship between generalized epileptic seizure and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and neutrophil mediated inflammation

Role of vascular cell adhesion molecules and leukocyte apoptosis in the lymphopenia and thrombocytopenia of patients with severe acute respiratory syndrome (SARS)

SARS-CoV proteins decrease levels and activity of human ENaC via activation of distinct PKC isoforms

In vitro large scale production of megakaryocytes to functional platelets from human hematopoietic stem cells

Cytokine control of megakaryopoiesis

Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan

Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia

Inactivation of three emerging viruses severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus -in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light

Proteomic analysis reveals platelet factor 4 and beta-thromboglobulin as prognostic markers in severe acute respiratory syndrome

Analysis of the level of selected parameters of inflammation,circulating immune complexes,and related indicators (neutrophil/lymphocyte, platelet/lymphocyte, CRP/CIC) in patients with obstructive diseases

Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Inflammatory impact of IFN-γ in CD8+T cellmediated lung injury is mediated by both Stat1-dependent and-independent pathways

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Host response to influenza virus: protection versus immunopathology

Cancer patients in SARS-CoV-2 infection:a nationwide analysis in China

Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

The dual role of plateletinnate immune cell interactions in thrombo-inflammation

Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia

Emerging novel Coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV

How to cite this article

Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19

All authors declare that there are no conflict of interests.

The authors of the manuscript declare contribution to the study.

http://orcid.org/0000-0003-2639-8216